NASDAQ:CDXS Codexis (CDXS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CDXS Stock Alerts $3.57 +0.01 (+0.28%) (As of 02:20 PM ET) Add Compare Share Share Today's Range$3.37▼$3.6350-Day Range$2.65▼$4.6552-Week Range$1.45▼$4.91Volume288,448 shsAverage Volume569,411 shsMarket Capitalization$251.90 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Codexis alerts: Email Address Codexis MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside95.4% Upside$6.80 Price TargetShort InterestHealthy3.36% of Shares Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.72Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector243rd out of 903 stocksIndustrial Organic Chemicals Industry6th out of 18 stocks 3.3 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCodexis has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.36% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Codexis has recently decreased by 0.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 3.2 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows2 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.30% of the stock of Codexis is held by insiders.Percentage Held by Institutions78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to decrease in the coming year, from ($0.60) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Codexis Stock (NASDAQ:CDXS)Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More CDXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXS Stock News HeadlinesMay 6, 2024 | americanbankingnews.comCodexis' (CDXS) "Buy" Rating Reiterated at BenchmarkMay 4, 2024 | finance.yahoo.comCodexis First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 3, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 3, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comCodexis Inc (CDXS) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic AdvancesMay 1, 2024 | markets.businessinsider.comHere's what to expect from Codexis's earningsMay 1, 2024 | msn.comCodexis Q1 2024 Earnings PreviewMay 7, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 26, 2024 | finance.yahoo.comWith 74% institutional ownership, Codexis, Inc. (NASDAQ:CDXS) is a favorite amongst the big gunsApril 19, 2024 | finance.yahoo.comCodexis, Inc. (CDXS)April 18, 2024 | globenewswire.comCodexis to Report First Quarter 2024 Financial Results on May 2April 11, 2024 | globenewswire.comCodexis Appoints Carole Cobb, MBA, to Strategic Advisory BoardMarch 30, 2024 | finance.yahoo.comFavourable Signals For Codexis: Numerous Insiders Acquired StockMarch 19, 2024 | seekingalpha.comAQST,CDXS and STI are among after hour moversMarch 1, 2024 | msn.comBenchmark raises Codexis to buy; cites Q4 earnings, guidanceMarch 1, 2024 | msn.comBenchmark Upgrades Codexis (CDXS)February 29, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS)February 29, 2024 | finance.yahoo.comCodexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deCodexis, Inc.: Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 29, 2024 | finance.yahoo.comQ4 2023 Codexis Inc Earnings CallFebruary 28, 2024 | benzinga.comRecap: Codexis Q4 EarningsFebruary 28, 2024 | msn.comCodexis GAAP EPS of -$0.10 beats by $0.04, revenue of $26.56M beats by $7.63MFebruary 28, 2024 | finance.yahoo.comCodexis Inc (CDXS) Reports Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comCodexis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | theglobeandmail.comBiotech Rallied Strongly On Exclusive Licensing AgreementFebruary 27, 2024 | marketwatch.comCodexis Shares Up 31% on Roche Licensing AgreementSee More Headlines Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/07/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Industrial organic chemicals Sub-IndustryBiotechnology Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees174Year FoundedN/APrice Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+90.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,240,000.00 Net Margins-87.73% Pretax Margin-108.59% Return on Equity-39.53% Return on Assets-24.00% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.53 Sales & Book Value Annual Sales$70.14 million Price / Sales3.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.88Miscellaneous Outstanding Shares70,560,000Free Float66,113,000Market Cap$251.90 million OptionableOptionable Beta2.04 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Stephen George Dilly MBBS (Age 64)Ph.D., President, CEO & Director Comp: $1.88MMr. Sriram Ryali M.B.A. (Age 43)Chief Financial Officer Comp: $770.45kMr. Kevin Norrett M.B.A. (Age 51)M.S., Chief Operating Officer Comp: $739.56kCarrie McKimDirector of Investor RelationsMs. Margaret Nell Fitzgerald J.D. (Age 53)Chief Legal & Compliance Officer, General Counsel and Secretary Comp: $300.03kMs. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesDr. Stefan Lutz Ph.D.Senior Vice President of ResearchMr. Robert Sato M.B.A.Ph.D., Senior Vice President of Pharmaceutical Development, Quality & RegulatoryMore ExecutivesKey CompetitorsAcrivon TherapeuticsNASDAQ:ACRVCandel TherapeuticsNASDAQ:CADLPrelude TherapeuticsNASDAQ:PRLDTrevi TherapeuticsNASDAQ:TRVIAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCSold 10,190 shares on 5/7/2024Ownership: 0.030%Baillie Gifford & Co.Bought 26,216 shares on 5/1/2024Ownership: 4.883%BNP Paribas Financial MarketsBought 83,436 shares on 5/1/2024Ownership: 0.144%Mirae Asset Global Investments Co. Ltd.Bought 24,978 shares on 5/1/2024Ownership: 0.035%Private Advisor Group LLCBought 41,855 shares on 4/30/2024Ownership: 0.328%View All Insider TransactionsView All Institutional Transactions CDXS Stock Analysis - Frequently Asked Questions Should I buy or sell Codexis stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks. What is Codexis' stock price target for 2024? 6 analysts have issued 12 month target prices for Codexis' shares. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $6.80 in the next year. This suggests a possible upside of 95.4% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts. How have CDXS shares performed in 2024? Codexis' stock was trading at $3.05 at the beginning of 2024. Since then, CDXS stock has increased by 14.1% and is now trading at $3.48. View the best growth stocks for 2024 here. When is Codexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CDXS earnings forecast. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.18. The biotechnology company earned $26.56 million during the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative trailing twelve-month return on equity of 39.53% and a negative net margin of 87.73%. What ETF holds Codexis' stock? Jacob Forward ETF holds 11,844 shares of CDXS stock, representing 1.20% of its portfolio. What guidance has Codexis issued on next quarter's earnings? Codexis updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $56.0 million-$64.0 million, compared to the consensus revenue estimate of $65.4 million. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). Who are Codexis' major shareholders? Codexis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (4.88%), Private Advisor Group LLC (0.33%), BNP Paribas Financial Markets (0.14%), Mirae Asset Global Investments Co. Ltd. (0.04%), SG Americas Securities LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDXS) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
